REG - GSK PLC - Transfer of Treasury Shares

GSKAnnouncement

22/03/2024 16:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240322:nRSV0288Ia&default-theme=true

RNS Number : 0288I  GSK PLC  22 March 2024

GSK plc

(the 'Company')

 

Transfer of Treasury Shares

 

 

On 21 March 2024, the Company transferred 27,800,000 ordinary shares of 31 1/4
pence each ("Ordinary Shares") that were held by the Company in treasury
("Treasury Shares") to JPMorgan Chase Bank, N.A., the depositary of the
Company's American depositary receipts ("ADR") programme, to procure the
issuance and transfer of 13,900,000 ADRs of the Company to the GlaxoSmithKline
(US) Trust (the "Trust"), to be used to satisfy awards granted under the
Company's Deferred Annual Bonus Plan, Performance Share Plan and Share Value
Plan. The consideration received from the trustee of the Trust of $41.93 per
ADR, representing $20.965 per Ordinary Share, was funded by a contribution to
the Trust from GlaxoSmithKline LLC.

 

Following the transfer and as at 22 March 2024, the Company's issued share
capital consisted of 4,314,051,101 Ordinary Shares, of which 169,171,155 were
held as Treasury Shares.

 

Therefore, the total number of voting rights in the Company is 4,144,879,946.
This figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under the Financial
Conduct Authority's Disclosure Guidance and Transparency Rules.

 

Notifications may be sent to company.secretary@gsk.com
(mailto:company.secretary@gsk.com) .

 

 

V A Whyte

Company Secretary

 

22 March 2024

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  POSFLFLRVAIFFIS